Goldman Sachs initiated coverage of Revolution Medicines (RVMD) with a Buy rating and $65 price target The firm says Revolution is a late stage clinical precision oncology company focused on developing a portfolio of RAS(On) inhibitors. Goldman sees blockbuster and underappreciated at current share levels commercial opportunities for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Strategic Growth and Financial Stability Drive Buy Rating
- Revolution Medicines announces collaboration with Iambic
- Truist biotech analyst holds an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Promising Prospects for Revolution Medicines’ Daraxonrasib in Pancreatic Cancer Treatment